Voglinorm-0.2/Voglinorm-0.3 Use In Pregnancy & Lactation

Use in pregnancy: To date, no relevant epidemiological data are available. Animal studies do not indicate harmful effects with respect to pregnancy, embryonal or fetal development, parturition or postnatal development, therefore, Voglinorm-0.2/Voglinorm-0.3 should be given to pregnant women or women suspected of being pregnant only when the potential benefits outweigh the possible hazards.
Use in lactation: Voglibose is excreted into milk in lactating rats. Similar data is not available in humans and a decision should be made whether to discontinue nursing or to discontinue voglibose in taking into account the benefit of using the compound in the mother. Animal studies (rats) have revealed a suppressive action of voglibose on body weight increase in newborns presumably due to suppression of milk production in mother animals resulting from suppression of carbohydrate absorption. Therefore, it is desirable not to give voglibose to women during lactation. When the administration is unavoidable, nursing should be avoided.